Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study

AIMS: Patients with pulmonary arterial hypertension associated with congenital heart disease (CHD‐PAH) after defect correction have a poor prognosis compared with other CHD‐PAH patients. Therefore, it is important that these patients are treated as early and effectively as possible. Evidence support...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Heart Fail
Main Authors: Beghetti, Maurice, Channick, Richard N., Chin, Kelly M., Di Scala, Lilla, Gaine, Sean, Ghofrani, Hossein‐Ardeschir, Hoeper, Marius M., Lang, Irene M., McLaughlin, Vallerie V., Preiss, Ralph, Rubin, Lewis J., Simonneau, Gérald, Sitbon, Olivier, Tapson, Victor F., Galiè, Nazzareno
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Ltd 2019
Assuntos:
Clinical Trials
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6607487/
https://ncbi.nlm.nih.gov/pubmed/30632656
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ejhf.1375
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados